← Back to Treatments
🏅 FDA Orphan Designation

EVRYSDI

RISDIPLAM

Manufacturer: Genentech, Inc.

Indicated for:
Distal hereditary motor neuropathyOrphanSpinal Muscular AtrophyOrphan

FDA-Approved Indications (2)

treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older

Spinal Muscular AtrophyOrphan Designation

1 INDICATIONS AND USAGE EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier indica…

Indications & Usage

1 INDICATIONS AND USAGE EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. ( 1 )

💙 Support Programs

View all →
EVRYSDI
Genentech, Inc.
Apply ↗
EVRYSDI
Genentech
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.